Respiratory Medicine
Volume 104, Issue 8 , Pages 1179-1188 , August 2010

Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat® inhaler versus MDI

  • R. ZuWallack

      Affiliations

    • St. Francis Hospital Medical Center, Hartford, CT 06105, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 860 714 4045.
    • ,
  • M.C. De Salvo

      Affiliations

    • Centro Medico Dra. de Salvo, Buenos Aires, Argentina
    • ,
  • T. Kaelin

      Affiliations

    • Lowcountry Lung Critical Care, Charleston, SC 29406, USA
    • ,
  • E.D. Bateman

      Affiliations

    • Dept of Medicine, University of Cape Town, Cape Town 7937, South Africa
    • ,
  • C.S. Park

      Affiliations

    • Soonchunhyang University Hospital Bucheon, Bucheon-Si 420-021, Korea
    • ,
  • R. Abrahams

      Affiliations

    • Morgantown Pulmonary Clinical Research, Morgantown, WV 26505, USA
    • ,
  • F. Fakih

      Affiliations

    • Florida Pulmonary Research Center, Winter Park, FL 32789, USA
    • ,
  • P. Sachs

      Affiliations

    • Pulmonary Associates of Stamford, Stamford, CT 06902, USA
    • ,
  • K. Pudi

      Affiliations

    • Upstate Pharmaceutical Research, Greenville, SC 29615, USA
    • ,
  • Y. Zhao

      Affiliations

    • Boehringer Ingelheim Pharmaceutical, Inc, Ridgefield, CT 06877, USA
    • ,
  • C.C. Wood

      Affiliations

    • Boehringer Ingelheim Pharmaceutical, Inc, Ridgefield, CT 06877, USA
    • ,
  • on behalf of the Combivent Respimat® inhaler Study Group

Received 4 November 2009 ,Accepted 23 January 2010.

References 

  1. Hochrainer D, Hölz H, Kreher C, Scaffiidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat® Soft Mist™ Inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18:S273–S282
  2. Zierenberg B. Optimizing the in vitro performance of Respimat®. J Aerosol Med. 1999;12(Suppl. 1):S19–S24
  3. Newman SP, Steed KP, Reader SJ, Hooper G, Zierenberg B. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci. 1996;85:960–964
  4. Newman SP, Brown J, Steed KP, Reader SJ, Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of Respimat with conventional metered-dose inhalers with and without spacer devices. Chest. 1998;113:957–963
  5. Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat® Soft Mist™ Inhaler compared to deposition by metered dose inhaler or by Turbuhaler® dry powder inhaler. J Aerosol Med. 2005;18:S264–S272
  6. Bone R, Boyars M, Braun SR, et al. for the Combivent Inhalation Aerosol Study Group In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest. 1994;105:1411–1419
  7. Dorinsky PM, Reisner C, Ferguson GT, Menjoge SS, Serby CW, Witek TJ. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with chronic obstructive pulmonary disease. Chest. 1999;115:966–971
  8. Chrischilles E, Gilden D, Kubisiak J, Rubenstein L, Shah H. Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two-in-one inhaler versus separate inhalers. Am J Manag Care. 2002;8:902–911
  9. American Thoracic Society . Standardization of spirometry: 1994 update. Am J Respir Crit Care Med. 1995;152:1107–1136
  10. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–338
  11. “Data on file, Boehringer-Ingelheim”.
  12. “Data on file, Boehringer-Ingelheim”.
  13. “Data on file, Boehringer-Ingelheim”.
  14. Tashkin DP, Celli B, Senn S, et al. for the UPLIFT study investigators A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1554
  15. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. for the TORCH investigators Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789
  16. Calverley P, Pauwels R, Vestbo J, et al. for The TRISTAN Study Group Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361:449–456
  17. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA for the INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19–26
  18. “Data on file, Boehringer-Ingelheim”.
  19. Schürmann W, Schmidtmann S, Moroni P, Massey D, Qidan M. Respimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction. Treat Respir Med. 2005;4:53–61
  20. Hodder RV, Schurmann W, Moroni P, Barczok M. Patients with obstructive lung disease prefer Respimat Soft Mist(TM) inhaler to pMDI. Chest. 2004;126:806s
  21. Kozma CM, Slaton TL, Monz BU, Hodder R, Reese PR. Development and validation of a patient satisfaction and preference questionnaire for inhalation devices. Treat Respir Med. 2005;4:41–52
  22. “Data on file, Boehringer-Ingelheim”.
  23. “Data on file, Boehringer-Ingelheim”.
  24. Kilfeather SA, Ponitz HH, Beck E, et al. Improved delivery of ipratropium bromide/fenoterol from Respimat® Soft Mist™ inhaler in patients with COPD. Respir Med. 2004;98:387–397

PII: S0954-6111(10)00044-2

doi: 10.1016/j.rmed.2010.01.017

Respiratory Medicine
Volume 104, Issue 8 , Pages 1179-1188 , August 2010

Article Tools

* Image Usage & Resolution